Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer.
Hongsik KimRyul KimHyunji JoHye Ryeon KimJoohyun HongSang Yun HaJoon Oh ParkSeung Tae KimPublished in: Therapeutic advances in gastroenterology (2022)
The present study suggests that the expression of PD-L1 alone was not sufficient as a novel marker to select advanced BTC patients who might benefit from ICIs. Additional comprehensive studies of biomarkers that can assist in predicting BTC patient responses to pembrolizumab and/or nivolumab therapy are required.